TY  - JOUR

T1  - 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study.

JO  - J Clin Oncol

PY  - 2008/05/20

AU  - Evans TR

AU  - Yellowlees A

AU  - Devine I

AU  - Earl HM

AU  - Cameron DA

AU  - Hutcheon AW

AU  - Coleman RE

AU  - Crown JP

AU  - Leonard RC

AU  - Mansi JL

ED  - 

VL  - 26

IS  - 15_suppl

SP  - 540

Y2  - 2025/10/10

ER  -